EQL Pharma AB (publ) (FRA:7JK)

Market Cap	152.64M
Revenue (ttm)	36.10M
Net Income (ttm)	2.68M
Shares Out	n/a
EPS (ttm)	0.09
PE Ratio	56.99
Forward PE	34.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	5.28
Previous Close	5.22
Day's Range	5.11 - 5.28
52-Week Range	4.29 - 8.80
Beta	n/a
RSI	57.22
Earnings Date	Feb 3, 2026

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 21
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7JK

Financial Performance

In 2024, EQL Pharma AB's revenue was 373.52 million, an increase of 41.39% compared to the previous year's 264.17 million. Earnings were 43.12 million, an increase of 89.93%.

Financial numbers in SEK